Pneumococcal Vaccine Market to Record a Robust Growth Rate During 2020 - 2024 | Pfizer, GSK, MSD, Sanofipasteur, CDIBP

Global Pneumococcal Vaccine Market 2020-2024 examines the market in detail along with focusing on significant market dynamics for the key players in the market. This research report offers granulated yet in-depth analysis of revenue share, market segments, revenue estimates and various regions across the globe.

Global Pneumococcal Vaccine Market overview:

The Pneumococcal Vaccine industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Pneumococcal Vaccine market size to maintain the average annual growth rate of 0.0138727890371 from 6310.0 million $ in 2014 to 6760.0 million $ in 2019, analysts believe that in the next few years, Pneumococcal Vaccine market size will be further expanded, we expect that by 2024, The market size of the Pneumococcal Vaccine will reach 7310.0 million $.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/205683 .

Pneumococcal vaccines are vaccines against the bacterium Streptococcus pneumoniae. Their use can prevent some cases of pneumonia, meningitis, and sepsis. There are two types of pneumococcal vaccines: conjugate vaccines and polysaccharide vaccines. The Global Pneumococcal Vaccine Market is segmented on the basis of Product Type, Application, End Use Industry and Region.

On the Basis of Product Type segment, the Pneumococcal Vaccine Market is sub segmented into PPSV 23, PCV 7/13 and PCV 10. Based on End Use Industry segment, the Pneumococcal Vaccine Market is sub segmented into Child and Adult.

Some of the Pneumococcal Vaccine Market manufacturers involved in the market are Pfizer, GSK, MSD, Sanofipasteur, CDIBP in World, effective mergers are some of the strategies adopted by the Pneumococcal Vaccine Market manufacturers. New product launches and continuous technological innovations are the Pneumococcal Vaccine Market strategies adopted by the major players.

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on "Pneumococcal Vaccine Market Report 2020" @ https://www.businessindustryreports.com/buy-now/205683/single .

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study.

There are several manufacturers of Pneumococcal Vaccines in Europe and North America. In North America, the demand for Pneumococcal Vaccines is primarily driven by the Pharmaceutical sector. Among the countries in Asia Pacific, the demand was substantially high in developing countries such as China and India. These countries have been witnessing rapid increase in its population along with expansion of their overall economies, which has led to increase in disposable income.

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/205683 .

Top Industry News:

GSK and Vir Biotechnology enter collaboration to find coronavirus solutions on 06 April, 2020-- GlaxoSmithKline plc and Vir Biotechnology, Inc. today announced they have signed a binding agreement to enter into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19.

The collaboration will use Vir's proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventative options to help address the current COVID-19 pandemic and future outbreaks. The companies will leverage GSK's expertise in functional genomics and combine their capabilities in CRISPR screening and artificial intelligence to identify anti-coronavirus compounds that target cellular host genes. They will also apply their combined expertise to research SARS-CoV-2 and other coronavirus vaccines.

Dr. Hal Barron, Chief Scientific Officer and President R&D, GSK, said: "Vir's unique antibody platform has precedented success in identifying and developing antibodies as treatments for multiple pathogens, and it is highly complementary with our R&D approach to focus on the science of immunology. I am very excited that the talent and passion of our two companies will come together to develop solutions for multiple diseases, including the very promising antibody candidates targeting COVID-19."

Due to the urgent patient need for COVID-19 solutions, the initial focus of the collaboration will be to accelerate the development of specific antibody candidates identified by the Vir platform, VIR-7831 and VIR-7832, that have demonstrated high affinity for the SARS-CoV-2 spike protein and are highly potent in neutralising SARS-CoV-2 in live virus-cellular assays. Subject to regulatory review, the companies plan to proceed directly into a phase 2 clinical trial within the next three to five months.

The collaboration will also utilise Vir's CRISPR screening and machine learning approach to identify cellular targets whose inhibition can prevent viral infection. Vir has identified multiple potential targets against flu and other respiratory pathogens, as well as hepatitis B virus, and will now focus on SARS-CoV-2.

Additionally, the companies have also agreed to conduct research into SARS-CoV-2 and other coronavirus vaccines by coupling GSK's vaccines technologies and expertise with Vir's ability to identify neutralising epitopes that are present across entire viral families. These efforts will be additive to other initiatives GSK is advancing to develop a potential vaccine for COVID-19.

Table of Contents:

1 Pneumococcal Vaccine Product Definition
2 Global Pneumococcal Vaccine Market Manufacturer Share and Market Overview
2.1 Global Manufacturer Pneumococcal Vaccine Shipments
2.2 Global Manufacturer Pneumococcal Vaccine Business Revenue
2.3 Global Pneumococcal Vaccine Market Overview
3 Manufacturer Pneumococcal Vaccine Business Introduction
3.1 Pfizer Pneumococcal Vaccine Business Introduction
3.1.1 Pfizer Pneumococcal Vaccine Shipments, Price, Revenue and Gross profit 2020-2024
3.1.2 Pfizer Pneumococcal Vaccine Business Distribution by Region
3.1.3 Pfizer Interview Record
3.1.4 Pfizer Pneumococcal Vaccine Business Profile
3.1.5 Pfizer Pneumococcal Vaccine Product Specification
3.2 GSK Pneumococcal Vaccine Business Introduction
3.2.1 GSK Pneumococcal Vaccine Shipments, Price, Revenue and Gross profit 2020-2024
3.2.2 GSK Pneumococcal Vaccine Business Distribution by Region
3.2.3 Interview Record
3.2.4 GSK Pneumococcal Vaccine Business Overview
3.2.5 GSK Pneumococcal Vaccine Product Specification
3.3 MSD Pneumococcal Vaccine Business Introduction
3.3.1 MSD Pneumococcal Vaccine Shipments, Price, Revenue and Gross profit 2020-2024
3.3.2 MSD Pneumococcal Vaccine Business Distribution by Region
3.3.3 Interview Record
3.3.4 MSD Pneumococcal Vaccine Business Overview
3.3.5 MSD Pneumococcal Vaccine Product Specification
3.4 Sanofipasteur Pneumococcal Vaccine Business Introduction
3.5 CDIBP Pneumococcal Vaccine Business Introduction
................... Request free sample to get a complete Table of Content

About us

BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined - we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune - India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.